Repository logo
  • English
  • Italiano
  • Log In
    Have you forgotten your password?
Repository logo
Repository logo
  • Archive
  • Series/Journals
  • EUT
  • Events
  • Statistics
  • English
  • Italiano
  • Log In
    Have you forgotten your password?
  1. Home
  2. EUT Edizioni Università di Trieste
  3. Atti di convegni
  4. Trans2Care
  5. Trans2Care, 2014. Cross-Border Italy-Slovenia Biomedical Research. Are we ready for Horizon 2020?
  6. Characterization and use of monoclonal antibodies against bilitranslocase and its determination in clear cell renal cell carcinoma
 
  • Details
  • Metrics
Options

Characterization and use of monoclonal antibodies against bilitranslocase and its determination in clear cell renal cell carcinoma

Rajcevic, Uros
•
et al.
2014
Loading...
Thumbnail Image
ISBN
978-88-8303-572-2
http://hdl.handle.net/10077/10273
  • Book Chapter

e-ISBN
978-88-8303-573-9
Abstract
With its worldwide incidence of about 300 000 new cases per year, clear cell Renal Cell Carcinoma (ccRCC) is the seventh most commonly diagnosed cancer in men and the ninth most commonly diagnosed cancer in women. At the hereditary and molecular levels recent research efforts describe large molecular profiling analyses for the molecular cause to be related with the development of ccRCC. Historically, von Hippel-Lindau (VHL) tumor suppressor protein located on chromosome 3p25, the loss of activity of which leads to a syndrome connected with diseases including ccRCC, was among the top genetic causes known. Monoclonal antibodies are an important tool in diagnostics and research, especially when we are dealing with a protein marker of unknown primary structure as in case of bilitranslocase (BTL). BTL is expressed on kidney cells, where it acts as an organic anion transporter. We have shown that there are differences in bilitranslocase expression in normal kidney cells versus early grade kidney cancer. A set of hybridoma cell lines producing antipeptide monoclonal antibodies against segments 235-246 (peptide B) and 298-310 (peptide C) of predicted primary structure of bilitranslocase was cloned by limiting dilution. With a sequence of immune tests we characterized monoclonal antibodies, and used them as a tool to distinguish between grades in progression of ccRCC. We developed monoclonal antibodies against extra- (peptide B) and intra-cellular (peptide C) domains of bilitranslocase protein model. Our results are showing that these antibodies can be used in different immunoassays. Furthermore specificity and affinity of our mAbs allowed us to assess progressive grades of clear cell renal cell carcinoma and thus introduce a potentially novel tool for the diagnostics of ccRCC.
Subjects
  • ccRCC

  • mAb

  • BTL

Publisher
EUT Edizioni Università di Trieste
Source
Uros Rajcevic, Alexandra Bogožalec, Tjaša Lukan, Mateja Kukovec, Vivijana Snoj, Sendi Montanič, Sabina Passamonti, Michela Terdoslavich and Vladka Čurin Šerbec, Characterization and use of monoclonal antibodies against bilitranslocase and its determination in clear cell renal cell carcinoma, in S. Passamonti, S. Gustincich, T. Lah Turnšek, B. Peterlin, R. Pišot, P. Storici (Eds.), Cross-border Italy-Slovenia biomedical research: are we ready for horizon 2020? Conference proceedings with an analysis of innovation management and knowledge transfer potential for a smart specialization strategy. Trieste, EUT Edizioni Università di Trieste, 2014, pp. 119-124
Languages
en
File(s)
Loading...
Thumbnail Image
Download
Name

Uros Rajcevic.pdf

Format

Adobe PDF

Size

458.09 KB

Indexed by

 Info

Open Access Policy

Share/Save

 Contacts

EUT Edizioni Università di Trieste

OpenstarTs

 Link

Wiki OpenAcces

Archivio Ricerca ArTS

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback